MICHAEL R PINSKY MD LLC

KAHR Bio will present Phase 2 data on DSP107, a first-in-class bi-specific 4-1BB T-cell engager, combined with atezolizumab for third-line microsatellite stable colorectal cancer at ASCO 2025.

• A 26-year-old bone cancer survivor has received the first known transplant of sperm-producing stem cells preserved from his childhood, marking a significant advancement in fertility preservation for pediatric cancer patients. • Approximately one-third of childhood cancer survivors face infertility from treatments, with prepubertal patients having limited options as they cannot bank mature reproductive cells before therapy. • The experimental procedure, developed at the University of Pittsburgh Medical Center, follows successful animal studies and represents a potential breakthrough in oncofertility, though researchers caution results remain uncertain.

Researchers have identified distinct metabolic signatures in pancreatic cancer patients using quantitative mass spectrometry, potentially offering new pathways for earlier diagnosis and survival prediction.

A phase 3 trial showed that adding perioperative atezolizumab to chemotherapy did not significantly improve event-free survival (EFS) in patients with triple-negative breast cancer (TNBC).